Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.C R Bard has entered into a license agreement with Genzyme to manufacture and market the Sepramesh IP hernia repair product line and to incorporate the related Sepra coating technology into the development of future hernia repair applications.
Subscribe to our email newsletter
Bard’s Davol subsidiary, located in Cranston, Rhode Island, will begin marketing the line immediately.
The Sepramesh IP product incorporates a polypropylene mesh with a layer of Sepra material on one side. The product combines the strength of a permanent implant with a bioresorbable hydrogel barrier to minimize tissue attachment to the mesh. This protective coating is absorbed over time, resulting in a permeable, flexible hernia repair.
Timothy Ring, chairman and CEO of Bard, said: “The Sepramesh IP product accelerates our entry into this space and represents a good growth opportunity for 2008 and beyond.”